ClinicalTrials.gg
Not yet recruitingNCT06830941Updated Feb 17, 2025

Iron Isomaltoside for the Treatment of Anemia in Peritoneal Dialysis Patients

A Phase 4 interventional study of Iron isomaltoside and Ferrous succinate in Renal Anemia and Peritoneal Dialysis (PD), sponsored by Xie Jingyuan, MD. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by Xie Jingyuan, MD · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing iron isomaltoside 1000 in Anemia — 11 open to participants now, 11 under way, 3 of them phase 3. iron isomaltoside 1000 · Anemia.

Planned enrollment
12th of 29
124 · median 120
Started
2025
with 5 others
Phase 4
13 of 29
6 open now
Primary completion
2027-02
later than 4 of 10 live
Registered
24th of 29
by date

Among the 29 studies testing iron isomaltoside 1000 in Anemia, this one is the 12th largest by planned enrollment, is one of 6 that started in 2025, is one of 13 in phase 4, reaches primary completion later than 4 of the 10 other live ones, and was the 24th registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

11 of the 29 studies testing iron isomaltoside 1000 in Anemia are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing iron isomaltoside 1000 in Anemia, or all of them as a file.
02

Study summary

This is a prospective multicenter randomized controlled clinical study. The goal of this clinical trial is to learn if intravenous iron isomaltoside injection use is equally effective and safe for the treatment of renal anemia in peritoneal dialysis patients compared with oral ferrous succinate tablets.

The main questions to answer are:

  • Changes in hemoglobin concentration from baseline to week 8 after the use of single dose intravenous iron isomaltoside injection in peritoneal dialysis patients with renal anemia.
  • If intravenous iron isomaltoside injection use is equally effective and safe for the treatment of renal anemia in peritoneal dialysis patients compared with oral ferrous succinate tablets.

Participants will:

  • be randomized 1:1 to two groups, either Iron isomaltoside Group (Group A, experimental group) or Ferrous succinate Group (Group B, control group).
  • Patients in Iron isomaltoside Group will receive a single dose of intravenous iron isomaltoside injection, the dose of which is set at 1000 mg. Patients in Ferrous succinate Group will receive ferrous succinate treatment orally given as 200mg twice a day for 8 weeks (containing iron element 7840mg in total).
  • Patients will be followed up for 8 weeks.
Read the detailed description

This is a prospective multicenter randomized controlled clinical study. The purpose of this study is to evaluate the efficacy and safety of single dose intravenous iron isomaltoside comparing with daily oral ferrous succinate in the treatment of renal anemia among patients on peritoneal dialysis.

A total of 124 patients will be enrolled. The primary endpoint is hemoglobin change from baseline to week 8, the secondary endpoint is hemoglobin change from baseline to week 4. Other secondary endpoints include the results of iron metabolism, reticulocytes, composite cardiovascular events, laboratory and safety parameters. The expected result is that intravenous iron isomaltoside is equally effective and safe for the treatment of renal anemia in peritoneal dialysis patients compared with oral ferrous succinate tablets.

03

Conditions studied

  • Renal Anemia
  • Peritoneal Dialysis (PD)

Browse trials for

Keywords

  • peritoneal dialysis
  • renal anemia
  • iron isomaltoside
  • iron treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females who are ≥ 18 years and on PD treatment for ≥90 days, body weight≥50Kg
  2. (Hb)≤110 g/L at screening phase
  3. Serum ferritin(SF)≤200 μg/L or transferrin saturation(TSAT)≤20% at screening phase
  4. No oral or intravenous iron use within 4 weeks prior to screening.
  5. No hypoxia-inducible factor prolyl hydroxylase inhibitor(HIF-PHI)used or other erythropoiesis-stimulating agent(ESA)except for erythropoietin (EPO) used in the past 4 weeks prior to screening
  6. Stable doses of erythropoiesis-stimulating agents (ESA) with a change of dose ≤20% during the past 4 weeks.
  7. Willing to participate and signed the form

Exclusion criteria

Exclusion Criteria:

  1. Anemia predominantly caused by other diseases rather than renal diseases according to the investigator's judgement. (eg. bleeding, hematological diseases, anemia due to diseases)
  2. History of disturbances in iron utilisation.(eg. hemochromatosis and hemosiderosis)
  3. Anemia due to lack of folate or vitamin B12:folate\<6.8nmol/L(3ng/ml)and(or) Vitamin B12\<74pmol/L(100pg/ml)at screening phase
  4. Histories of serious allergies to iron
  5. Obvious liver dysfunction:>3× and/or AST>3×ULN,or total >1.5×ULN
  6. Active acute or chronic infection(clinically diagnosed)
  7. Uncontrolled secondary hyperparathyroidism:PTH or iPTH>9×ULN;
  8. History of within 5 years
  9. Acute coronary syndrome, strokes (except for lacunar cerebral infarction), serious thromboembolism (eg. DVT or PE) within 6 months before the screening period
  10. grade III or IV of congestive heart failure or severe arrythmia(including ventricular tachycardia, ventricular fibrillation, AV-block III etc.) within 6 months before screening
  11. Pregnant or during lactation period or not willing to get
  12. Planning to receive renal transplantation within 2 months
  13. Accepted blood transfusion within 3 months.
  14. Serum ferritin,SF>500 μg/L
  15. Planning to recieve the treatment as operations, chemotherapies or radiotherapies etc. during the research period
  16. Other situations not suitable for inclusion decided by researchers. Rescreening is allowed if it failed in the first time of screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Iron isomaltoside Group

    Intravenous infusion of 1000mg iron isomaltoside as a single dose for over 15min. Iron isomaltoside 1000mg was diluted in 100ml of 0.9% saline.

    Drug: Iron isomaltoside

  • Active comparator
    Ferrous succinate Group

    Patients received ferrous succinate treatment orally given as 200mg twice a day for 8 weeks(containing iron element 7840mg in total).

    Drug: Ferrous succinate

Interventions

  • DrugIron isomaltoside 1000Studies of Iron isomaltoside 1000Iron isomaltoside 1000 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous infusion of 1000mg iron isomaltoside as a single dose for over 15min. Iron isomaltoside 1000mg was diluted in 100ml of 0.9% saline.

    Also known as: Intravenous iron isomaltoside

  • Patients received ferrous succinate treatment orally given as 200mg twice a day for 8 weeks.

    Also known as: Oral ferrous succinate

06

What researchers measure

Primary outcomes

  1. Changes in hemoglobin concentration from baseline to week 8

    Full blood count

    Time frame: Screening period,Day 1,Week 1,Week 4,Week 8

Secondary outcomes

  1. Changes in hemoglobin concentration from baseline to week 4

    Full blood count

    Time frame: Screening period,Day 1,Week 1,Week 4

  2. Iron metabolism indices and reticulocyte count at week 8

    Iron metabolism indices and reticulocyte count

    Time frame: Screening period,Day 1,Week 1,Week 4,Week 8

  3. Iron metabolism indices and reticulocyte count at week 4

    Iron metabolism indices and reticulocyte count

    Time frame: Screening period,Day 1,Week 1,Week 4

  4. Compound cardiovascular adverse events at Week 8

    Recording and observation with the reference of clinical symptoms and the results of EKG, NT-proBNP, cardiac troponin, CK-MB and myoglobin etc.

    Time frame: Through study completion, an average of 1 year

  5. Adverse Events

    Recording and observation with the reference of clinical symptoms and the results of laboratory indices and other indices for safety

    Time frame: Through study completion, an average of 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016 Apr;31(4):646-55. doi: 10.1093/ndt/gfv293. Epub 2015 Aug 6. PubMed 26250435 ↗
  • Bhandari S, Kalra PA, Kothari J, Ambuhl PM, Christensen JH, Essaian AM, Thomsen LL, Macdougall IC, Coyne DW. A randomized, open-label trial of iron isomaltoside 1000 (Monofer(R)) compared with iron sucrose (Venofer(R)) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015 Sep;30(9):1577-89. doi: 10.1093/ndt/gfv096. Epub 2015 Apr 28. PubMed 25925701 ↗
  • Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2021 Jan 1;36(1):111-120. doi: 10.1093/ndt/gfaa011. PubMed 32049331 ↗
  • Futterer S, Andrusenko I, Kolb U, Hofmeister W, Langguth P. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal. 2013 Dec;86:151-60. doi: 10.1016/j.jpba.2013.08.005. Epub 2013 Aug 14. PubMed 23998966 ↗
  • Jahn MR, Andreasen HB, Futterer S, Nawroth T, Schunemann V, Kolb U, Hofmeister W, Munoz M, Bock K, Meldal M, Langguth P. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011 Aug;78(3):480-91. doi: 10.1016/j.ejpb.2011.03.016. Epub 2011 Mar 23. PubMed 21439379 ↗
  • Auerbach M, Henry D, DeLoughery TG. Intravenous ferric derisomaltose for the treatment of iron deficiency anemia. Am J Hematol. 2021 Jun 1;96(6):727-734. doi: 10.1002/ajh.26124. Epub 2021 Feb 26. PubMed 33580972 ↗
  • Auerbach M, Gafter-Gvili A, Macdougall IC. Intravenous iron: a framework for changing the management of iron deficiency. Lancet Haematol. 2020 Apr;7(4):e342-e350. doi: 10.1016/S2352-3026(19)30264-9. PubMed 32220343 ↗
  • Bazeley JW, Wish JB. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review. Am J Kidney Dis. 2022 Jun;79(6):868-876. doi: 10.1053/j.ajkd.2021.09.017. Epub 2021 Nov 7. PubMed 34758368 ↗
  • Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, Haya-Palazuelos J, Ciria-Recasens M, Manasanch J, Perez-Edo L. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013 Apr;29(4):291-303. doi: 10.1185/03007995.2012.761599. Epub 2013 Feb 6. PubMed 23252877 ↗
  • Drueke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012 Nov;82(9):952-60. doi: 10.1038/ki.2012.270. Epub 2012 Aug 1. PubMed 22854645 ↗
  • Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol. 2020 Mar;31(3):456-468. doi: 10.1681/ASN.2019020213. Epub 2020 Feb 10. PubMed 32041774 ↗
  • Molnar MZ, Mehrotra R, Duong U, Kovesdy CP, Kalantar-Zadeh K. Association of hemoglobin and survival in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2011 Aug;6(8):1973-81. doi: 10.2215/CJN.01050211. Epub 2011 Jul 22. PubMed 21784829 ↗
  • Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int. 2004 May;65(5):1864-9. doi: 10.1111/j.1523-1755.2004.00584.x. PubMed 15086928 ↗
  • Horl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol. 2013 May;9(5):291-301. doi: 10.1038/nrneph.2013.21. Epub 2013 Feb 26. PubMed 23438972 ↗
  • Fishbane S, Spinowitz B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. Am J Kidney Dis. 2018 Mar;71(3):423-435. doi: 10.1053/j.ajkd.2017.09.026. Epub 2018 Jan 11. PubMed 29336855 ↗
  • Cheng CK, Chan J, Cembrowski GS, van Assendelft OW. Complete blood count reference interval diagrams derived from NHANES III: stratification by age, sex, and race. Lab Hematol. 2004;10(1):42-53. doi: 10.1532/lh96.04010. PubMed 15070217 ↗
  • Yang C, Yang Z, Wang J, Wang HY, Su Z, Chen R, Sun X, Gao B, Wang F, Zhang L, Jiang B, Zhao MH. Estimation of Prevalence of Kidney Disease Treated With Dialysis in China: A Study of Insurance Claims Data. Am J Kidney Dis. 2021 Jun;77(6):889-897.e1. doi: 10.1053/j.ajkd.2020.11.021. Epub 2021 Jan 7. PubMed 33421457 ↗
  • GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020 Feb 29;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3. Epub 2020 Feb 13. PubMed 32061315 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Feb 2027, 23 months later.

Of 60 non-industry phase 4 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 48. This study's planned 23 months is close to that.

Counting every sponsor, half of 74 studies reached it within 25 months; a quarter within 17 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 17, 2025
StartEst.
Feb 15, 2025
Primary completionEst.
Feb 9, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06830941
Lead sponsor
Xie Jingyuan, MD
Collaborators
RenJi Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Songjiang Hospital, Shanghai Jiao Tong University School of Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Chinese People's Liberation Army No 455 Hospital
Responsible party
Xie Jingyuan, MD (professor, Ruijin Hospital) — Sponsor-investigator
First posted
Feb 17, 2025
Start date
Feb 15, 2025 (estimated)
Primary completion
Feb 9, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 17, 2025

Study contacts

Jingyuan Xie
Contact
nephroxie@163.com
+862164370045 ext. 665272

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion